April 2025, Vol 2, No 4
USU researchers noted they used observational retrospective analysis, with longitudinal data from the National Healthcare Safety Network that included about 48 hospitals and researcher surveys for both inpatient and outpatient clinics to take a more comprehensive, system-wide look at ASPs, since most available data has been at the facility level, rather than the entire system. Read More ›
DCTs involve collaboration between study sponsors, research teams, the National TeleOncology Service, and participant sites. Read More ›
At the end of March, officials with the US Department of Health and Human Services (HHS) announced a restructuring that they claimed in a prepared statement will “serve multiple goals without impacting critical services.” Read More ›
Officials with the FDA have approved the first subcutaneous apomorphine infusion (Onapgo; Supernus) for patients with Parkinson’s disease (PD). Read More ›
Two years after leaving the TRICARE Pharmacy Program network, the Kroger Family of Pharmacies has rejoined the TRICARE Pharmacy Program network. Read More ›
With more than 400 nominations this year, the AMSUS Award Ceremony underscored the dedication and excellence of healthcare professionals across federal service. Read More ›
The FDA has approved a rapid-acting human insulin biosimilar to Novolog (Novo Nordisk), insulin-aspart-szjj (Merilog; Sanofi-Aventis), for glycemic control in adults and pediatric patients with diabetes mellitus. Read More ›
The FDA has given the MEK inhibitor mirdametinib (Gomekli; SpringWorks) approval for the treatment of adult and pediatric patients aged ≥2 years with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PNs) not amenable to complete resection.1 With the approval, SpringWorks was granted a rare pediatric disease Priority Review Voucher by the FDA. Read More ›
Officials with Bavarian Nordic A/S have announced that the FDA has approved their recombinant chikungunya vaccine (Vimkunya) for injection, the first virus-like particle single-dose chikungunya vaccine in the United States for persons aged ≥12 years. Read More ›
Officials with AbbVie have announced that the FDA has approved aztreonam and avibactam (Emblaveo; AbbVie), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. Read More ›